Australian OGTR Authorizes Clinical Trial of GM Influenza VaccineJune 17, 2020
The Office of the Gene Technology Regulator of Australia has issued license DIR 171 to Clinical Network Services (CNS) Pty Ltd, authorizing clinical trial of a live genetically modified (GM) vaccine against influenza virus infection. The Risk Assessment and Risk Management Plan (RARMP) and the license were finalized taking into account the input received during a consultation with the public, State and Territory governments, Australian Government agencies, the Minister for the Environment, the Gene Technology Technical Advisory Committee and local councils.
The finalized RARMP concludes that this clinical trial poses negligible risks to the health and safety of people and the environment, thus it does not require specific risk treatment measures. However, the RARMP states that the license conditions have been imposed to limit the size, location, and duration of the clinical trial and to restrict the spread and persistence of the GMOs and their genetic material in the environment.
The finalized RARMP, a summary of the RARMP, license, and Questions and Answers about this decision are available online from the DIR 171 page of the OGTR website.
You might also like:
- First Human Trial of COVID-19 Vaccine Found Safe and Induces Rapid Immune Response
- Researchers in Spain Use Biotech to Produce SARS-CoV-2 Vaccine in Plants
- Viable Vaccine Candidate for COVID-19 Developed Using Proprietary Plant-based Technology
The Crop Biotech Update is a weekly newsletter of ISAAA, a non-for-profit organization. The CBU is distributed for free to over 23,000 subscribers worldwide to inform them about the key developments in biosciences, especially in agricultural biotechnology. Your support will help us in our mission to feed the world with knowledge. You can help by donating as little as $10.
See more articles:
- Scientists Find Super-potent Human Antibodies from Recovered COVID-19 Patients
News from Around the World
- Soil Health Trailblazer is 2020 World Food Prize Laureate
- Genome Editing 101: Healthcare and Industrial Applications and Regulations
- Australian OGTR Authorizes Clinical Trial of GM Influenza Vaccine
- World Experts Release Roadmap for Next Generation Crops
- Israeli Scientists Discover Possibilities of Plant-Sustained Electricity
- Study Reveals Transgenic Goats Can be Used to Produce Antibodies Against Cancer
- OsCpn60β1 Vital for Chloroplast Development in Rice, Study
Plant Breeding Innovations
- High-Efficiency Reduction of Rice Amylose Content via CRISPR-Cas9-Mediated Base Editing
- New Protocol: Genome Editing Using Rice Zygotes
Subscribe to CBU: